Javascript must be enabled to continue!
Controlled release of FGF‐2 using fragmin/protamine microparticles and effect on neovascularization
View through CrossRef
AbstractWater‐insoluble fragmin/protamine microparticles of about 0.5–1 μm in diameter were prepared by simple mixing of low‐molecular‐weight heparin (fragmin) with protamine. We investigated the capability of these microparticles to immobilize fibroblast growth factor (FGF)‐2, to protect FGF‐2 against degradation, to enhance FGF‐2 activity, and to facilitate controlled release of FGF‐2. FGF‐2 bound to the fragmin/protamine microparticles with high affinity (Kd = 2.08 × 10−9 M) and the half‐life of FGF‐2‐activity was prolonged substantially through binding of FGF‐2 to the microparticles, by protection of FGF‐2 from inactivation by heat and proteolysis. After subcutaneous injection into the back of mice, the fragmin/protamine microparticles underwent biodegradation and disappeared in about 2 weeks. A similar injection of FGF‐2‐containing microparticles resulted in significant neovascularization and fibrous tissue formation near the injection site after 1 week. These results indicate that controlled release of biologically active FGF‐2 occurs through both slow diffusion and biodegradation of the microparticles, with subsequent induction of neovascularization. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009
Title: Controlled release of FGF‐2 using fragmin/protamine microparticles and effect on neovascularization
Description:
AbstractWater‐insoluble fragmin/protamine microparticles of about 0.
5–1 μm in diameter were prepared by simple mixing of low‐molecular‐weight heparin (fragmin) with protamine.
We investigated the capability of these microparticles to immobilize fibroblast growth factor (FGF)‐2, to protect FGF‐2 against degradation, to enhance FGF‐2 activity, and to facilitate controlled release of FGF‐2.
FGF‐2 bound to the fragmin/protamine microparticles with high affinity (Kd = 2.
08 × 10−9 M) and the half‐life of FGF‐2‐activity was prolonged substantially through binding of FGF‐2 to the microparticles, by protection of FGF‐2 from inactivation by heat and proteolysis.
After subcutaneous injection into the back of mice, the fragmin/protamine microparticles underwent biodegradation and disappeared in about 2 weeks.
A similar injection of FGF‐2‐containing microparticles resulted in significant neovascularization and fibrous tissue formation near the injection site after 1 week.
These results indicate that controlled release of biologically active FGF‐2 occurs through both slow diffusion and biodegradation of the microparticles, with subsequent induction of neovascularization.
© 2008 Wiley Periodicals, Inc.
J Biomed Mater Res, 2009.
Related Results
Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity
Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity
AbstractProtamine sulfate blocked 125I‐PDGF binding to its specific physiological receptor on Swiss mouse 3T3 cells. Reduced 125I‐PDGF binding in the presence of protamine sulfate ...
Negative Regulation by p70 S6 Kinase of FGF-2–Stimulated VEGF Release Through Stress-Activated Protein Kinase/c-Jun N-Terminal Kinase in Osteoblasts
Negative Regulation by p70 S6 Kinase of FGF-2–Stimulated VEGF Release Through Stress-Activated Protein Kinase/c-Jun N-Terminal Kinase in Osteoblasts
Abstract
To clarify the mechanism of VEGF release in osteoblasts, we studied whether p70 S6 kinase is involved in basic FGF-2–stimulated VEGF release in osteoblast-l...
Expression of osteoclastogenic factor transcripts in osteoblast‐like UMR‐106 cells after exposure to FGF‐23 or FGF‐23 combined with parathyroid hormone
Expression of osteoclastogenic factor transcripts in osteoblast‐like UMR‐106 cells after exposure to FGF‐23 or FGF‐23 combined with parathyroid hormone
AbstractAs a bone‐derived hormone, fibroblast growth factor‐23 (FGF‐23) negatively regulates phosphate and calcium metabolism, while retaining growth‐promoting action for mesenchym...
Fabrication of glipizide loaded polymeric microparticles; in-vitro and in-vivo evaluation
Fabrication of glipizide loaded polymeric microparticles; in-vitro and in-vivo evaluation
Controlled-release microparticles offer a promising avenue for enhancing patient compliance and minimizing dosage frequency. In this study, we aimed to design controlled-release mi...
Preparation and evaluation of biodegradable rifampicin microparticles using supercritical fluid technique for pulmonary delivery
Preparation and evaluation of biodegradable rifampicin microparticles using supercritical fluid technique for pulmonary delivery
It is of interest to apply a supercritical fluid technology for production of inhalable biodegradable microparticles of rifampicin. The polyhydroxy acids[poly(DL-lactide-co-glvcoli...
Heparin-protamine management: a comparison study of three different heparin-protamine management protocols
Heparin-protamine management: a comparison study of three different heparin-protamine management protocols
In a prospective randomized open study, 180 patients underwent open-heart surgery using cardiopulmonary bypass (CPB) and were divided into three different heparin-protamine managem...
Optimal Protamine Dosing for Heparin Reversal in Cardiopulmonary Bypass: A Quasi-Experimental Study in Elective Coronary Artery Bypass Surgery
Optimal Protamine Dosing for Heparin Reversal in Cardiopulmonary Bypass: A Quasi-Experimental Study in Elective Coronary Artery Bypass Surgery
Objectives: Protamine sulfate is routinely administered after cardiopulmonary bypass (CPB) to neutralize heparin; however, conventional 1:1 heparin–protamine dosing may exceed the ...
Expression of FGF receptor gene in rat development
Expression of FGF receptor gene in rat development
Abstract
We examined the expression of FGF-receptor (FGF-R) mRNA during rat development with in situ hybridization histochemistry. Embryonic tissues (E9, E12, E14, E...

